Epigral Ltd Q4 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/y6gsocygo4hyku6jrm5xkbz9.pdf

Key Takeaways


Volume Growth & the Realization Reset

Maulik Patel: "FY '23 has been an exciting year even after a lot of volatility for the business. The realizations for all the products were at peak at the starting of the year and have reached to a bottom level by the end of the year. Even after this, our top line for the year as a whole has increased by 41% to INR2,196 crores."

Derivatives Ramp: ECH, CPVC & the Portfolio Shift

Milind Kotecha: "So if you track both the things put together, then you will see the margin has remained intact. But again, we would definitely not buy on spot and sell on spot. So again, the raw material that we have in our hand, with that lag only, there will be an impact on a margin for that particular quarter or maybe six months, till the time inventory I have. Otherwise, on a normal basis, one can, I mean, in this particular range, 25% to 30% margin is achievable."

Chlorotoluene: The Next Growth Leg

Maulik Patel: "This is a first time in India, we have started focusing on this project in India. And we have already started a construction. Our project is almost 60% to 70% is completed. And we are going to commission by quarter for this financial year."

Geopolitical Tailwinds & Export Opportunity

Maulik Patel: "So all those volume people are thinking now to manufacture in India. So Yes indirectly because of whatever the reasons Ukraine war or the Trump tax or we are getting indirectly advantage as a Indian as a chemical manufacturing."

Margins, Costs & the Energy Equation

Milind Kotecha: "Our margins will remain in this range 28% plus minus two so worst case 25 and the best-case kind of a 30 but when we are entering into this derivative products our focus is on the ROCE which will improve like if compared to what we had, when we were just in chloralkali."

End-Market Demand & Sector Exposure

Maulik Patel: "As a India we believe that in India I think the still I think we are far away from that deadline. And I don't think so till 2,000 I think in 2032 I think we are going to continue with the refrigerant gas what we have right now."

Guidance & Commitments

CommitmentSpecificsTimeline
Volume growth15% to 20% volume growthFY24
Value growth20% plus revenue growthFY24
EBITDA marginSustainable at 28% plus/minus 2% (range 25-30%)FY24 and coming years
Derivative revenue shareReach 50% of total revenue (from 38% in Q4 FY23)By end of current financial year
In-house chlorine consumptionReach 75% (from 65% currently)When CPVC resin and chlorotoluene plants are commissioned
In-house chlorine consumptionReach 85%In two to three years
Chlorotoluene Phase 1Commissioning; targeting more than INR300 crores turnover, minimum 25% ROCEQ4 FY23
CPVC capacity expansionIncrease from 30,000 TPA to approximately 45,000 TPAVolume contribution in FY25
Revenue ambitionINR5,000 croresBy FY27
Export shareRise to 9-10% of company revenue (from ~4% in FY23)FY24
ECH utilizationIncrease quarter-on-quarter from 40%From Q1 FY24 onward
Solar/renewable powerFirst phase commissioningFrom next month onward (post-Q4 FY23)

Key Metrics

MetricQ4 FY23
Revenue from operations₹562 cr, +13% YoY
FY23 revenue from operations₹2,188 cr, +41% YoY
FY23 PAT₹353 cr, +40% YoY
EBITDA margin~28%, company as a whole
Sustainable EBITDA margin guidance28% ±2%, worst case 25%, best case 30%
Volume growth+15% YoY and +13% QoQ
FY24 volume growth expectation15% to 20%
FY24 value growth expectation~20%+
Derivative and specialty chemical segment revenue contribution38% of revenue, vs 19% in Q4 FY22
Derivative revenue target by end of FY2450% of total revenue
Caustic soda ECU realization~₹38,000
Caustic soda capacity utilization~78% on increased capacity of 4 lakh tons per annum
ECH realization~₹1,20,000 to ₹1,25,000
ECH capacity utilization~40%
CPVC realization~₹1,50,000 to ₹1,60,000
CPVC capacity utilization~90%
Hydrogen peroxide capacity utilization~98% to 100%
Hydrogen peroxide realization~₹27,000
Chloromethane realization~₹40,000 to ₹45,000
Chloromethane price change~-10% QoQ
Chlorine consumption in-house65%, target 85% in 2–3 years
Chlorine realization~-₹2,000
Exports as percentage of total revenue~4% in FY23, expected 9–10% in FY24
ECH export vs domestic split40% exports, 60% domestic at current situation
FY23 capex spent₹416 cr, vs ₹456 cr in FY22
Net debt₹877 cr, decreased by ₹112 cr vs FY22
Net debt-to-EBITDA1.3x, improved from 1.9x in FY22
Net debt equity0.08x, vs 1.3x in FY22
Return on capital employed (FY23)32%, vs 29% in FY22
Return on equity (FY23)40%, vs 36% in FY22
Proposed final dividend₹2.5 per equity share, 25% on face value of ₹10
Coal price change+30% YoY, -15% QoQ
Power generation cost change-14% QoQ
Chlorotoluene Phase 1 revenue target>₹300 cr turnover
Chlorotoluene Phase 1 ROCE target≥25%
Long-term revenue target₹5,000 cr by FY27